YolTech at Hope for Rare Science Conference 2026

From June 25–27, 2026, Dr. Yuxuan Wu, Co-founder and Chief Executive Officer of YolTech, was invited to present at the Hope for Rare Science Conference (HRSC) in Shanghai. During the Gene Therapy session, he shared the Company's latest progress in developing in vivo gene editing therapies for rare genetic diseases and exchanged perspectives with researchers, clinicians and industry leaders from around the world.

Launched by the Hope for Rare Foundation in 2022, HRSC is a biennial conference dedicated to rare disease research and translational medicine. The conference brings together the global rare disease community to foster scientific exchange and collaboration across academia, healthcare, industry and patient organizations.

During his presentation, Dr. Wu discussed the evolving landscape of in vivo gene editing and its potential to address the significant unmet needs of patients with rare genetic diseases. He shared updates on YolTech's research and development efforts, including progress across the Company's rare disease pipeline, and discussed the opportunities and challenges of advancing innovative gene editing therapies from research into clinical development.

"For many rare genetic diseases, gene editing is opening the door to entirely new treatment possibilities," said Dr. Wu. "At YolTech, we are focused on developing innovative medicines that address significant unmet medical needs. By advancing our pipeline and translating scientific discoveries into clinical programs, we aim to bring new treatment options to patients."